Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 2, 2010, Pages 602-609

  Meletiadis, Joseph ^a,d   Pournaras, Spyros ^b   Roilides, Emmanuel ^c,d   Walsh, Thomas J ^d  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; RAVUCONAZOLE; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPERGILLUS FUMIGATUS; COLORIMETRY; CORRELATION ANALYSIS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG POTENTIATION; EXPERIMENTAL MODEL; FRACTIONAL INHIBITORY CONCENTRATION; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LUNG ASPERGILLOSIS; MONTE CARLO METHOD; NONHUMAN; PRIORITY JOURNAL; SPECTROPHOTOMETRY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; COLORIMETRY; CONFIDENCE INTERVALS; DRUG THERAPY, COMBINATION; INVASIVE PULMONARY ASPERGILLOSIS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; PYRIMIDINES; TRIAZOLES;

EID: 75749101383     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00999-09     Document Type: Article

References (27)

1. American Society for Microbiology. 2004. Instructions to authors. Antimicrob. Agents Chemother. 48:i-xxi.
2. Berenbaum, M. C. 1980. Correlations between methods for measurement of synergy. J. Infect. Dis. 142:476-480.
3. Berenbaum, M. C. 1987. Minor synergy and antagonism may be clinically important. J. Antimicrob. Chemother. 19:271-273.
4. Berenbaum, M. C. 1989. What is synergy? Pharmacol. Rev. 41:93-141.
5. Clemons, K. V., M. Espiritu, R. Parmar, and D. A. Stevens. 2005. Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and VRC alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob. Agents Chemother. 49:4867-4875.
6. Clinical and Laboratory Standards Institute. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. NCCLS document M38-A. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Cuenca-Estrella, M., A. Gomez-Lopez, G. Garcia-Effron, L. Alcazar-Fuoli, E. Mellado, M. J. Buitrago, and J. L. Rodriguez-Tudela. 2005. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob. Agents Chemother. 49:1232-1235.
8. Eliopoulos, G., and R. C. Moellering, Jr. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams & Wilkins Co., Baltimore, MD.
9. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
10. Groll, A. H., and T. J. Walsh. 2002. Antifungal chemotherapy: advances and perspectives. Swiss Med. Wkly. 132:303-311.
11. Hall, M. J., R. F. Middleton, and D. Westmacott. 1983. The fractional inhibitory concentration (FIC) index as a measure of synergy. J. Antimicrob. Chemother. 11:427-433.
12. Johnson, M. D., C. MacDougall, L. Ostrosky-Zeichner, J. R. Perfect, and J. H. Rex. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715.
13. Kirkpatrick, W. R., S. Perea, B. J. Coco, and T. F. Patterson. 2002. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. 46:2564-2568.
14. MacCallum, D. M., J. A. Whyte, and F. C. Odds. 2005. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob. Agents Chemother. 49:3697-3701.
15. Marr, K. A., M. Boeckh, R. A. Carter, H. W. Kim, and L. Corey. 2004. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39:797-802.
16. Meletiadis, J., J. W. Mouton, J. F. Meis, B. A. Bouman, J. P. Donnelly, and P. E. Verweij. 2001. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39:3402-3408.
17. Meletiadis, J., J. W. Mouton, J. F. Meis, B. A. Bouman, P. J. Donnelly, and P. E. Verweij. 2001. Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis{2-methoxy-4-nitro-5- [(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide}, for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39:4256-4263.
18. Meletiadis, J., J. W. Mouton, J. L. Rodriguez-Tudela, J. F. Meis, and P. E. Verweij. 2000. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob. Agents Chemother. 44:470-472.
19. Meletiadis, J., J. W. Mouton, D. T. A. te Dorsthorst, and P. E. Verweij. 2005. Assessing combination of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med. Mycol. 43:133-152.
20. Meletiadis, J., V. Petraitis, R. Petraitiene, P. Lin, T. Stergiopoulou, A. M. Kelaher, T. Sein, R. L. Schaufele, J. Bacher, and T. J. Walsh. 2006. Triazolepolyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J. Infect. Dis. 194:1008-1018.
21. Meletiadis, J., D. T. te Dorsthorst, and P. E. Verweij. 2006. The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions. Int. J. Antimicrob. Agents 28:439-449.
22. Odds, F. C. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
23. Patterson, T. F., W. R. Kirkpatrick, M. White, J. W. Hiemenz, J. R. Wingard, B. Dupont, M. G. Rinaldi, D. A. Stevens, and J. R. Graybill. 2000. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 79:250-260.
24. Perea, S., G. Gonzalez, A. W. Fothergill, W. R. Kirkpatrick, M. G. Rinaldi, and T. F. Patterson. 2002. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. 46:3039-3041.
25. Petraitis, V., R. Petraitiene, W. W. Hope, J. Meletiadis, T. Stergiopoulou, D. Mickiene, M. P. Cotton, M. Kasai, A. Francesconi, J. E. Hughes, R. Schaufele, M. Sein, N. A. Avila, J. Bacher, and T. J. Walsh. 2009. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose-dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob. Agents Chemother. 53:2382-2391.
26. Rand, K. H., H. J. Houck, P. Brown, and D. Bennett. 1993. Reproducibility of the microdilution checkerboard method for antibiotic synergy. Antimicrob. Agents Chemother. 37:613-615.
27. Sionov, E., S. Mendlovic, and E. Segal. 2006. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J. Infect. 53:131-139.